ONX-7: eligible for CR-01 · confidence ≥ 70%

Patients needing attention

Synthetic demo data

Biological stateToxicity risk ≥Discontinuation risk ≥Predicted response ≥Predicted response ≤Days on treatment ≥Days on treatment ≤ClusterPrior interventionEligible forConfidence ≥

Clear

patients · ONX-7: eligible for CR-01 · confidence ≥ 70%

Create intervention

Most common reason

GI intolerance

Most effective previous action

GI-04

Nutritional protocol

Estimated addressable population

eligible for GI-04, confidence ≥ 70%

Predicted persistence gain

+17%

Patient	Day	Baseline	GI	Tolerance	GI score	Discontinuation	Cluster
P-03323	148	S14	Unstable	Stable	62	96%	EC-03
P-03332	98	S14	Unstable	Stable	77	96%	EC-03
P-03341	142	S14	Unstable	Deteriorating	71	96%	EC-03
P-03345	145	S14	Unstable	Deteriorating	73	96%	EC-03
P-03413	150	S14	Unstable	Improving	78	96%	EC-03
P-03285	119	S04	Unstable	Deteriorating	73	94%	LT
P-03430	121	S14	Unstable	Improving	61	92%	EC-03
P-03460	127	S11	Unstable	Deteriorating	63	88%	EC-03
P-03037	140	S14	Unstable	Stable	66	87%	EC-03
P-03145	139	S14	Deteriorating	Deteriorating	57	87%	EC-03
P-03030	147	S14	Unstable	Deteriorating	66	82%	EC-03
P-03120	109	S14	Unstable	Deteriorating	61	81%	LT
P-03293	134	S14	Unstable	Deteriorating	70	78%	EC-03
P-03378	105	S10	Deteriorating	Deteriorating	55	75%	LT
P-03070	147	S14	Deteriorating	Favorable	55	73%	EC-03
P-03251	110	S14	Unstable	Improving	66	73%	EC-03
P-03300	150	S14	Deteriorating	Favorable	47	73%	EC-03
P-03280	145	S13	Unstable	Deteriorating	67	70%	LT
P-03384	144	S01	Unstable	Improving	66	69%	LT
P-03080	145	S09	Unstable	Unstable	66	62%	LT
P-03405	105	S16	Deteriorating	Deteriorating	53	62%	LT
P-03052	145	S03	Deteriorating	Favorable	46	59%	MR
P-03103	92	S14	Stable	Favorable	44	59%	EC-03
P-03081	143	S10	Stable	Deteriorating	53	58%	EC-03